



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Gomekli Prior Authorization Policy

- Gomekli™ (mirdametininib tablets – SpringWorks Therapeutics)

**REVIEW DATE:** 02/11/2026

---

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## **CIGNA NATIONAL FORMULARY COVERAGE:**

### **OVERVIEW**

Gomekli, a kinase inhibitor, is indicated for the treatment of neurofibromatosis type 1 (NF1) in adults and pediatric patients 2 years of age and older with symptomatic plexiform neurofibromas (PN) not amenable to complete resection.<sup>1</sup>

### **Disease Overview**

NF1 is an autosomal dominant genetic condition due to loss-of-function variants in the *NF1* gene.<sup>2</sup> The birth incidence for NF1 is approximately 1 per 2,500. This gene variant results in persistent mitogen-activated protein kinase (MAPK) pathway activation and neurofibromin dysfunction. PNs are non-malignant nerve sheath tumors that develop in 30% to 50% of patient with NF1; this type of tumor causes pain, organ displacement/compression, impaired physical function, disfigurement, and deteriorated quality of life. PN tumors can transform into malignant peripheral nerve sheath tumors. Surgery is the primary treatment for NF1 with PN. However, it is associated with life-altering morbidities and tumor regrowth. Koselugo®

(selumetinib capsules) is FDA-approved for the treatment of pediatric patients 2 years and older with NF1 and symptomatic, inoperable PN.<sup>3</sup>

## **Guidelines**

The National Comprehensive Cancer Network (NCCN) central nervous system (CNS) cancers guidelines (version 3.2025 – December 5, 2025) recommend Gomekli as “Useful in Certain Circumstances” for NF1 who have symptomatic plexiform neurofibromas not amenable to complete resection (category 2A).<sup>4</sup>

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Gomekli. All approvals are provided for the duration noted below.

**Gomekli™ (mirdametininb tablets - SpringWorks Therapeutics) is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

## **FDA-Approved Indication**

- 1. Neurofibromatosis Type 1.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
  - A)** Patient is  $\geq 2$  years of age; AND
  - B)** According to the prescriber, patient has or had symptomatic plexiform neurofibromas prior to starting Gomekli; AND
  - C)** According to the prescriber, the tumor is not amenable to complete resection.

## **CONDITIONS NOT COVERED**

**Gomekli™ (mirdametininb tablets - SpringWorks Therapeutics) is(are) considered not medically necessary for ANY other use(s); criteria will be updated as new published data are available):**

## **REFERENCES**

1. Gomekli™ capsules [prescribing information]. Stamford, CT: SpringWorks Therapeutics; February 2025.
2. Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal, phase IIb trial of mirdametininb in adults and children with symptomatic neurofibromatosis type 1 – associated plexiform neurofibroma. *J Clin Oncol* 2025;43(6):716-729..
3. Koselugo® capsules [prescribing information]. Wilmington, DE: AstraZeneca; November 2025
4. The NCCN Central Nervous System Cancers Clinical Practice Guidelines in Oncology (version 3.2025 – December 5, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on January 28, 2026.

## HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	02/19/2025
DEU Update	03/27/2025: Added Guidelines section in Overview to address Gomekli.	--
Annual Revision	<b>Neurofibromatosis Type 1:</b> "According to the prescriber" was added to the requirement that the tumor is not amenable to complete resection.	02/11/2026

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.